Page 5 - Otonomy Inc News Today

Sage Therapeutics (NASDAQ:SAGE – Get Rating) and Otonomy (NASDAQ:OTIC – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership. Profitability This table compares Sage Therapeutics and Otonomy’s net margins, […]

SAN DIEGO, May 18, 2022 -- Otonomy, Inc. , a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the H.C.... | May 18, 2022

– Data reconfirm previously highlighted safety and efficacy potential of AGTC-501 as a treatment for X-linked retinitis pigmentosa (XLRP) – ...

Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss - read this article along with other careers information, tips and advice on BioSpace

Applied Genetic Technologies (NASDAQ:AGTC – Get Rating) and TRACON Pharmaceuticals (NASDAQ:TCON – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership. Earnings and Valuation This table compares Applied Genetic […]

Applied Genetic Technologies (NASDAQ:AGTC – Get Rating) and TRACON Pharmaceuticals (NASDAQ:TCON – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Risk and Volatility Applied Genetic Technologies has a […]

GAINESVILLE, Fla., and CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical...

StockNews.com assumed coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a report released on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock. Separately, Zacks Investment Research lowered shares of Otonomy from a “buy” rating to a “hold” rating in a report on Friday, March 4th. OTIC opened at $2.30 […]

Otonomy, Inc. (NASDAQ:OTIC – Get Rating) CEO David Allen Weber sold 8,026 shares of the stock in a transaction that occurred on Friday, March 25th. The stock was sold at an average price of $2.39, for a total transaction of $19,182.14. The transaction was disclosed in a document filed with the SEC, which is available […]

Otonomy, Inc. (NASDAQ:OTIC – Get Rating) CEO David Allen Weber sold 11,243 shares of the stock in a transaction on Monday, March 28th. The stock was sold at an average price of $2.41, for a total transaction of $27,095.63. The transaction was disclosed in a document filed with the SEC, which is available at this […]